Skip to main content
Erschienen in: Strahlentherapie und Onkologie 10/2012

01.10.2012 | Original article

Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer

A comparative plan analysis

verfasst von: C. Song, H. Pyo, M.D., Ph.D., J. Kim, Y.K. Lim, W.C. Kim, H.J. Kim, D.W. Kim, K.H. Cho

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare helical tomotherapy (HT) and conventional intensity-modulated radiotherapy (IMRT) using a variety of dosimetric and radiobiologic indexes in patients with locally advanced non-small cell lung cancer (LA-NSCLC).

Patients and methods

A total of 20 patients with LA-NSCLC were enrolled. IMRT plans with 4–6 coplanar beams and HT plans were generated for each patient. Dose distributions and dosimetric indexes for the tumors and critical structures were computed for both plans and compared.

Results

Both modalities created highly conformal plans. They did not differ in the volumes of lung exposed to > 20 Gy of radiation. The average mean lung dose, volume receiving ≥ 30 Gy, and volume receiving ≥ 10 Gy in HT planning were 18.3 Gy, 18.5%, and 57.1%, respectively, compared to 19.4 Gy, 25.4%, and 48.9%, respectively, with IMRT (p = 0.004, p < 0.001, and p < 0.001). The differences between HT and IMRT in lung volume receiving ≥ 10–20 Gy increased significantly as the planning target volume (PTV) increased. For 6 patients who had PTV greater than 700 cm3, IMRT was superior to HT for 5 patients in terms of lung volume receiving ≥ 5–20 Gy. The integral dose to the entire thorax in HT plans was significantly higher than in IMRT plans.

Conclusion

HT gave significantly better control of mean lung dose and volume receiving ≥ 30–40 Gy, whereas IMRT provided better control of the lung volume receiving ≥ 5–15 Gy and the integral dose to entire thorax. In most patients with PTV greater than 700 cm3, IMRT was superior to HT in terms of lung volume receiving ≥ 5–20 Gy. It is therefore advised that caution should be exercised when planning LA-NSCLC using HT.
Literatur
1.
Zurück zum Zitat Belderbos J, Heemsbergen W, Hoogeman M et al (2005) Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75:157–164PubMedCrossRef Belderbos J, Heemsbergen W, Hoogeman M et al (2005) Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75:157–164PubMedCrossRef
2.
Zurück zum Zitat Bral S, Duchateau M, Versmessen H et al (2010) Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys 77:1352–1359PubMedCrossRef Bral S, Duchateau M, Versmessen H et al (2010) Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys 77:1352–1359PubMedCrossRef
3.
Zurück zum Zitat Brenner DJ, Doll R, Goodhead DT et al (2003) Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 100:13761–13766PubMedCrossRef Brenner DJ, Doll R, Goodhead DT et al (2003) Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 100:13761–13766PubMedCrossRef
4.
Zurück zum Zitat Cattaneo GM, Dell’oca I, Broggi S et al (2008) Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiother Oncol 88:310–318PubMedCrossRef Cattaneo GM, Dell’oca I, Broggi S et al (2008) Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiother Oncol 88:310–318PubMedCrossRef
5.
Zurück zum Zitat Chang CC, Chi KH, Kao SJ et al (2011) Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer 73:189–194PubMedCrossRef Chang CC, Chi KH, Kao SJ et al (2011) Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer 73:189–194PubMedCrossRef
6.
Zurück zum Zitat Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRef Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRef
7.
Zurück zum Zitat Gagliardi G, Lax I, Rutqvist LE (2001) Partial irradiation of the heart. Semin Radiat Oncol 11:224–233PubMedCrossRef Gagliardi G, Lax I, Rutqvist LE (2001) Partial irradiation of the heart. Semin Radiat Oncol 11:224–233PubMedCrossRef
8.
Zurück zum Zitat Gopal R, Tucker SL, Komaki R et al (2003) The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 56:106–113PubMedCrossRef Gopal R, Tucker SL, Komaki R et al (2003) The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 56:106–113PubMedCrossRef
9.
Zurück zum Zitat Hayman JA, Martel MK, Ten Haken RK et al (2001) Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19:127–136PubMed Hayman JA, Martel MK, Ten Haken RK et al (2001) Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19:127–136PubMed
10.
Zurück zum Zitat Hsieh CH, Chang HT, Lin SC et al (2010) Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment—case report. BMC Cancer 10:696PubMedCrossRef Hsieh CH, Chang HT, Lin SC et al (2010) Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment—case report. BMC Cancer 10:696PubMedCrossRef
11.
Zurück zum Zitat Kron T, Grigorov G, Yu E et al (2004) Planning evaluation of radiotherapy for complex lung cancer cases using helical tomotherapy. Phys Med Biol 49:3675–3690PubMedCrossRef Kron T, Grigorov G, Yu E et al (2004) Planning evaluation of radiotherapy for complex lung cancer cases using helical tomotherapy. Phys Med Biol 49:3675–3690PubMedCrossRef
12.
Zurück zum Zitat Kutcher GJ, Burman C (1989) Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 16:1623–1630PubMedCrossRef Kutcher GJ, Burman C (1989) Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 16:1623–1630PubMedCrossRef
13.
Zurück zum Zitat Liao ZX, Komaki RR, Thames HD Jr et al (2010) Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76:775–781PubMedCrossRef Liao ZX, Komaki RR, Thames HD Jr et al (2010) Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76:775–781PubMedCrossRef
14.
Zurück zum Zitat Liu HH, Jauregui M, Zhang X et al (2006) Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers. Int J Radiat Oncol Biol Phys 65:561–572PubMedCrossRef Liu HH, Jauregui M, Zhang X et al (2006) Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers. Int J Radiat Oncol Biol Phys 65:561–572PubMedCrossRef
15.
Zurück zum Zitat Mackie TR, Holmes T, Swerdloff S et al (1993) Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 20:1709–1719PubMedCrossRef Mackie TR, Holmes T, Swerdloff S et al (1993) Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 20:1709–1719PubMedCrossRef
16.
Zurück zum Zitat Mavroidis P, Shi C, Plataniotis GA et al (2011) Comparison of the helical tomotherapy against the multileaf collimator-based intensity-modulated radiotherapy and 3D conformal radiation modalities in lung cancer radiotherapy. Br J Radiol 84:161–172PubMedCrossRef Mavroidis P, Shi C, Plataniotis GA et al (2011) Comparison of the helical tomotherapy against the multileaf collimator-based intensity-modulated radiotherapy and 3D conformal radiation modalities in lung cancer radiotherapy. Br J Radiol 84:161–172PubMedCrossRef
17.
Zurück zum Zitat Murshed H, Liu HH, Liao Z et al (2004) Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1258–1267PubMedCrossRef Murshed H, Liu HH, Liao Z et al (2004) Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1258–1267PubMedCrossRef
18.
Zurück zum Zitat Rao M, Yang W, Chen F et al (2010) Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: plan quality, delivery efficiency and accuracy. Med Phys 37:1350–1359PubMedCrossRef Rao M, Yang W, Chen F et al (2010) Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: plan quality, delivery efficiency and accuracy. Med Phys 37:1350–1359PubMedCrossRef
19.
Zurück zum Zitat Rengan R, Rosenzweig KE, Venkatraman E et al (2004) Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60:741–747PubMedCrossRef Rengan R, Rosenzweig KE, Venkatraman E et al (2004) Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60:741–747PubMedCrossRef
20.
Zurück zum Zitat Rong Y, Tang G, Welsh JS et al (2011) Helical tomotherapy versus single-arc intensity-modulated arc therapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys 81:284–296PubMedCrossRef Rong Y, Tang G, Welsh JS et al (2011) Helical tomotherapy versus single-arc intensity-modulated arc therapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys 81:284–296PubMedCrossRef
21.
Zurück zum Zitat Shueng PW, Lin SC, Chang HT et al (2009) Toxicity risk of non-target organs at risk receiving low-dose radiation: case report. Radiat Oncol 4:71PubMedCrossRef Shueng PW, Lin SC, Chang HT et al (2009) Toxicity risk of non-target organs at risk receiving low-dose radiation: case report. Radiat Oncol 4:71PubMedCrossRef
22.
Zurück zum Zitat Song CH, Pyo H, Moon SH et al (2010) Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 78:651–658PubMedCrossRef Song CH, Pyo H, Moon SH et al (2010) Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 78:651–658PubMedCrossRef
23.
Zurück zum Zitat Sterzing F, Schubert K, Sroka-Perez G et al (2008) Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. Strahlenther Onkol 184:8–14PubMedCrossRef Sterzing F, Schubert K, Sroka-Perez G et al (2008) Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. Strahlenther Onkol 184:8–14PubMedCrossRef
24.
Zurück zum Zitat Sterzing F, Welzel T, Sroka-Perez G et al (2009) Reirradiation of multiple brain metastases with helical tomotherapy. A multifocal simultaneous integrated boost for eight or more lesions. Strahlenther Onkol 185:89–93PubMedCrossRef Sterzing F, Welzel T, Sroka-Perez G et al (2009) Reirradiation of multiple brain metastases with helical tomotherapy. A multifocal simultaneous integrated boost for eight or more lesions. Strahlenther Onkol 185:89–93PubMedCrossRef
25.
Zurück zum Zitat Uhl M, Sterzing F, Habl G et al (2012) Breast cancer and funnel chest. Comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum. Strahlenther Onkol 188:127–135PubMedCrossRef Uhl M, Sterzing F, Habl G et al (2012) Breast cancer and funnel chest. Comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum. Strahlenther Onkol 188:127–135PubMedCrossRef
26.
Zurück zum Zitat Vogelius IS, Westerly DC, Cannon GM et al (2011) Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. Int J Radiat Oncol Biol Phys 80:893–899PubMedCrossRef Vogelius IS, Westerly DC, Cannon GM et al (2011) Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. Int J Radiat Oncol Biol Phys 80:893–899PubMedCrossRef
27.
Zurück zum Zitat Wiezorek T, Brachwitz T, Georg D et al (2011) Rotational IMRT techniques compared to fixed gantry IMRT and tomotherapy: multi-institutional planning study for head-and-neck cases. Radiat Oncol 6:20PubMedCrossRef Wiezorek T, Brachwitz T, Georg D et al (2011) Rotational IMRT techniques compared to fixed gantry IMRT and tomotherapy: multi-institutional planning study for head-and-neck cases. Radiat Oncol 6:20PubMedCrossRef
28.
Zurück zum Zitat Wiezorek T, Schwahofer A, Schubert K (2009) The influence of different IMRT techniques on the peripheral dose: a comparison between sMLM-IMRT and helical tomotherapy. Strahlenther Onkol 185:696–702PubMedCrossRef Wiezorek T, Schwahofer A, Schubert K (2009) The influence of different IMRT techniques on the peripheral dose: a comparison between sMLM-IMRT and helical tomotherapy. Strahlenther Onkol 185:696–702PubMedCrossRef
29.
Zurück zum Zitat Yom SS, Liao Z, Liu HH et al (2007) Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:94–102PubMedCrossRef Yom SS, Liao Z, Liu HH et al (2007) Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:94–102PubMedCrossRef
30.
Zurück zum Zitat Yorke ED, Jackson A, Rosenzweig KE et al (2005) Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63:672–682PubMedCrossRef Yorke ED, Jackson A, Rosenzweig KE et al (2005) Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63:672–682PubMedCrossRef
31.
Zurück zum Zitat Zibold F, Sterzing F, Sroka-Perez G et al (2009) Surface dose in the treatment of breast cancer with helical tomotherapy. Strahlenther Onkol 185:574–581PubMedCrossRef Zibold F, Sterzing F, Sroka-Perez G et al (2009) Surface dose in the treatment of breast cancer with helical tomotherapy. Strahlenther Onkol 185:574–581PubMedCrossRef
Metadaten
Titel
Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer
A comparative plan analysis
verfasst von
C. Song
H. Pyo, M.D., Ph.D.
J. Kim
Y.K. Lim
W.C. Kim
H.J. Kim
D.W. Kim
K.H. Cho
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 10/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0159-3

Weitere Artikel der Ausgabe 10/2012

Strahlentherapie und Onkologie 10/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.